Pharma Focus Asia

Novel Novilase® Interstitial Laser System Developed for Breast Cancer

Novian Health Inc. developed Novilase® Interstitial Laser System for the treatment of malignant breast tumors for adult women who undergo breast conserving procedure. The laser therapy helps patients by keeping away from trauma and works as an alternative for breast cancer surgery.

Novilase is a minimally invasive procedure which destroys tumors with the use of laser ablation resulting as an alternative procedure to surgery. This is applicable for the focal damaging of malignant tumors of the breast up to 15 mm including incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues.

In U.S, every year more than 275,000 women and approximately 2 million in the world are diagnosed with breast cancer.

Lumpectomy, is a surgical procedure for breast cancer. Most of the breast cancer patients and their doctors prefer to remove tumors surgically in breast-conserving procedure called lumpectomy. Though patients treated with this procedure 25 percent of women may need additional surgery as the entire tumors are not removed during the initial surgical procedure.

In Novilase procedure, laser probe is inserted directly into the tumor by using ultrasound guidance. The tumor is then heated by the laser and destroyed.   

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Novilase® Interstitial Laser System for the treatment of breast cancer.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference